{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:28:01Z","timestamp":1773815281587,"version":"3.50.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>DNMT3A mutations occur in 20-25% of acute myeloid leukemia (AML) cases and are associated with poor prognosis, yet the epigenetic mechanisms underlying treatment response remain poorly understood. Traditional methylation analyses focus on mean levels, overlooking the heterogeneity that may be central to therapeutic vulnerability. We developed a Local Promoter Methylation Disorder (LPMD) algorithm to quantify methylation instability and evaluate its clinical utility in predicting azacitidine response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The LPMD algorithm was developed using the GSE62298 dataset (68 AML patients: 15 DNMT3A-mutant, 53 wild-type) to quantify local methylation heterogeneity through a 1-kb sliding window across CpG sites. Algorithm performance was validated in an independent WGBS cohort (20 AML samples) and further confirmed via R882-stratified analysis in the TCGA-LAML cohort (n = 194). Clinical predictive value was assessed in GSE152710 (63 high-risk MDS\/secondary AML patients receiving azacitidine), where differentially methylated disorder regions (DMDRs) were identified and a consensus feature selection strategy was employed to construct a predictive panel. Longitudinal samples (n\u00a0= 153) enabled treatment dynamics analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The LPMD algorithm effectively captured DNMT3A mutation-associated epigenetic instability (Cohen\u2019s d = 0.8,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001), with the strongest effects observed in the 5\u2019UTR-Exon1 region (d = 0.74) and a gradient pattern from CpG islands to shores (d: 0.59\u21920.54\u21920.43). Genome-wide scanning identified 7,097 DMDRs exhibiting a striking bidirectional pattern: 85.3% showed decreased disorder (aberrant stabilization) while 14.7% showed increased disorder (maintenance failure), with the latter enriched in promoters (91% of high-priority DMDRs). Although genome-wide LPMD failed to predict azacitidine response, a 5-DMDR panel derived from multi-algorithm consensus achieved AUC\u00a0=\u00a00.777, 81% sensitivity, and 73% specificity. Treatment monitoring revealed a significant LPMD decrease at 3\u20135 months (-3.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001), defining a critical window for efficacy assessment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The LPMD algorithm reframes DNMT3A-mutant AML from a hypomethylation paradigm to a methylation disorder paradigm, revealing dual mechanisms of aberrant stabilization and maintenance failure at distinct genomic regions. The 5-DMDR panel offers a practical tool for azacitidine response prediction, while dynamic LPMD monitoring provides a potential biomarker for therapeutic guidance. These findings establish methylation disorder as a clinically actionable dimension of epigenetic dysregulation in myeloid malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1795605","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:35:22Z","timestamp":1773812122000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Local Promoter Methylation Disorder algorithm reveals bidirectional epigenetic disruption in DNMT3A-mutated AML and predicts azacitidine treatment response"],"prefix":"10.3389","volume":"16","author":[{"given":"Xin","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Guizhou Provincial People\u2019s Hospital","place":["Guiyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuqiang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Center for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University","place":["Guiyang, China"]},{"name":"School of Clinical Laboratory Science, Guizhou Medical University","place":["Guiyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benfan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Linyi People\u2019s Hospital","place":["Linyi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaomiao","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Second People\u2019s Hospital of Guiyang (Jinyang Hospital)","place":["Guiyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"key":"B2","volume-title":"SEER Cancer Statistics Review. National Cancer Institute. Acute Myeloid Leukemia (AML) 5-year survival rates, 2021","year":""},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05885-8","article-title":"Significance of targeting DNMT3A mutations in AML","volume":"103","author":"Huang","year":"2024","journal-title":"Ann Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-367961","article-title":"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia","volume":"119","author":"Ribeiro","year":"2012","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2022","article-title":"Simpson's paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia","volume":"33","author":"Gale","year":"2015","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukemic hematopoietic stem cells in acute leukemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81656-6","article-title":"DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development","volume":"99","author":"Okano","year":"1999","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.02.010","article-title":"The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers","volume":"25","author":"Russler-Germain","year":"2014","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.366625","article-title":"Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation","volume":"287","author":"Holz-Schietinger","year":"2012","journal-title":"J Biol Chem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.021","article-title":"CpG island hypermethylation mediated by DNMT3A is a consequence of AML progression","volume":"168","author":"Spencer","year":"2017","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014698","article-title":"Double mutant DNMT3A AML: a unique subtype experiencing increased DNA damage and poor prognosis","volume":"9","author":"Boertjes","year":"2025","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205699","article-title":"5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy","volume":"21","author":"Christman","year":"2002","journal-title":"Oncogene"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1038\/s41467-025-59796-x","article-title":"Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs","volume":"16","author":"Thoms","year":"2025","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13148-023-01580-z","article-title":"Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen","volume":"15","author":"Schmutz","year":"2023","journal-title":"Clin Epigenet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300445","article-title":"Cellular composition and 5hmC signature predict the treatment response of AML patients to azacitidine combined with chemotherapy","volume":"10","author":"Liang","year":"2023","journal-title":"Adv Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.012","article-title":"Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia","volume":"26","author":"Landau","year":"2014","journal-title":"Cancer Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4125","article-title":"Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia","volume":"22","author":"Li","year":"2016","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3811","article-title":"Potential energy landscapes identify the information-theoretic nature of the epigenome","volume":"49","author":"Jenkinson","year":"2017","journal-title":"Nat Genet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41467-024-55691-z","article-title":"Increased local DNA methylation disorder in AMLs with DNMT3A-destabilizing variants and its clinical implication","volume":"16","author":"Lee","year":"2025","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr017","article-title":"Genome-wide quantitative assessment of variation in DNA methylation patterns","volume":"39","author":"Xie","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2442","article-title":"Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues","volume":"44","author":"Landan","year":"2012","journal-title":"Nat Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10478","article-title":"DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer","volume":"7","author":"Teschendorff","year":"2016","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.1038\/ncomms7921","article-title":"Epigenomic evolution in diffuse large B-cell lymphomas","volume":"6","author":"Pan","year":"2015","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3230","article-title":"Functions of DNA methylation: islands, start sites, gene bodies and beyond","volume":"13","author":"Jones","year":"2012","journal-title":"Nat Rev Genet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.07.028","article-title":"Gene body methylation can alter gene expression and is a therapeutic target in cancer","volume":"26","author":"Yang","year":"2014","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal2380","article-title":"Epigenetic plasticity and the hallmarks of cancer","volume":"357","author":"Flavahan","year":"2017","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","first-page":"13242","DOI":"10.1038\/s41598-018-31635-8","article-title":"The DNMT3A R882H mutation does not cause dominant negative effects in purified mixed DNMT3A\/R882H complexes","volume":"8","author":"Emperle","year":"2018","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nature05987","article-title":"DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA","volume":"448","author":"Ooi","year":"2007","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.6","article-title":"Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells","volume":"29","author":"Spencer","year":"2015","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3488","article-title":"DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia","volume":"48","author":"Oakes","year":"2016","journal-title":"Nat Genet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-018-0004-3","article-title":"DNA methylation-based biomarkers and the epigenetic clock theory of ageing","volume":"19","author":"Horvath","year":"2018","journal-title":"Nat Rev Genet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.06.067","article-title":"Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes","volume":"20","author":"Unnikrishnan","year":"2017","journal-title":"Cell Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601231103","article-title":"Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer","volume":"103","author":"Ein-Dor","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.12.029","article-title":"Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells","volume":"21","author":"Tsai","year":"2012","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1032","article-title":"Epigenetic identity in AML depends on disruption of nonpromoter regulatory elements and is affected by antagonistic effects of mutations in epigenetic modifiers","volume":"7","author":"Glass","year":"2017","journal-title":"Cancer Discov"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3646","article-title":"Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution","volume":"48","author":"Corces","year":"2016","journal-title":"Nat Genet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/ng.865","article-title":"Increased methylation variation in epigenetic domains across cancer types","volume":"43","author":"Hansen","year":"2011","journal-title":"Nat Genet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2011.07.007","article-title":"High density DNA methylation array with single CpG site resolution","volume":"98","author":"Bibikova","year":"2011","journal-title":"Genomics"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4161\/epi.6.6.16196","article-title":"Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome","volume":"6","author":"Sandoval","year":"2011","journal-title":"Epigenetics"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation","volume":"44","author":"Challen","year":"2012","journal-title":"Nat Genet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-300145","article-title":"Prdm16 is a physiologic regulator of hematopoietic stem cells","volume":"117","author":"Aguilo","year":"2011","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ccell.2016.05.008","article-title":"Epigenetic perturbations by Arg882-mutated DNMT3A potentiate aberrant stem cell gene-expression program and acute leukemia development","volume":"30","author":"Lu","year":"2016","journal-title":"Cancer Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.03.010","article-title":"PRDM16 suppresses MLL1r leukemia via intrinsic histone methyltransferase activity","volume":"62","author":"Zhou","year":"2016","journal-title":"Mol Cell"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2187","article-title":"Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia","volume":"16","author":"Kharas","year":"2010","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01179-9","article-title":"Somatic mutations and cell identity linked by genotyping of transcriptomes","volume":"54","author":"Nam","year":"2022","journal-title":"Nat Genet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1795605\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:35:24Z","timestamp":1773812124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1795605\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":54,"alternative-id":["10.3389\/fonc.2026.1795605"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1795605","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1795605"}}